妊娠相关早期黑色素瘤的母婴结局:澳大利亚人群回顾性队列研究
该研究基于澳大利亚新南威尔士州1994至2013年178万余次妊娠的回顾性队列,比较妊娠期与产后早期(0-II期)黑色素瘤诊断者的围产期及生存结局。结果显示原位于妊娠期或产后诊断的早期黑色素瘤未显著增加母婴不良结局,两组死亡率无显著差异,早期诊断仍是关键。
要点
- 妊娠期或产后诊断的早期黑色素瘤未显著增加母婴不良结局。
- 2002至2013年原位黑色素瘤年发病率上升8.7%(95%CI 4.0-13.5)。
- 局限型原发侵袭性黑色素瘤发病率在1994至2013年无上升。
核心结论
- 妊娠期或产后诊断早期黑色素瘤与母婴显著不良结局无关,早期诊断对确保适当治疗和良好结局仍重要。
研究设计与样本
- 澳大利亚新南威尔士州人群回顾性队列研究,纳入1994年1月1日至2013年12月31日分娩的女性及其婴儿,死亡数据随访至2018年9月。
- 共识别1,785,876次妊娠,其中妊娠期黑色素瘤223例(228名婴儿),产后黑色素瘤467例(478名婴儿),对照组为无癌症诊断的分娩女性。
- 围产期结局采用广义估计方程模型比较,死亡率采用Cox回归、Kaplan-Meier曲线和log-rank检验比较。
主要发现
- 2002至2013年间原位黑色素瘤发病率每年增加8.7%(95%CI 4.0-13.5)。
- 1994至2013年间局限型原发侵袭性黑色素瘤发病率无增加。
- 未发现显著的母体或新生儿疾病。
- 妊娠期黑色素瘤与产后黑色素瘤女性死亡率无显著差异(2.4/1000人年 vs. 1.6/1000人年,p值=0.394)。
临床怎么用
- 妊娠期或产后诊断的早期黑色素瘤未显著增加母婴不良结局,临床可据此进行围产期管理咨询。
- 早期诊断仍是确保适当治疗和良好结局的关键。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pregnancy-associated melanoma (PAM) is melanoma diagnosed during pregnancy or the 12 months postpartum. There is long-standing debate regarding the impact of pregnancy on melanoma prognosis. Previous studies have analysed pooled data from PAM diagnoses of all stages, so findings may not reflect outcomes associated with the diagnosis of in situ or localized PAM that are more commonly diagnosed than later stage PAM. OBJECTIVES: To describe the incidence, perinatal and survival outcomes of in situ or localized primary invasive PAM (melanoma stages 0-II). METHODS: A population-based retrospective cohort study in New South Wales (NSW), Australia was performed, comprising women who birthed between 1 January 1994 and 31 December 2013 and their babies, with mortality data available until September 2018. Women were grouped as gestational PAM (diagnosed with early-stage melanoma during pregnancy), postpartum PAM (diagnosed with early-stage melanoma within 1 year postpartum) or control (women who gave birth without a diagnosis of cancer). Perinatal outcomes were compared using generalized estimating equation models and mortality compared using Cox regression, Kaplan-Meier curves and the log-rank test. RESULTS: In total, 1,785,876 pregnancies were identified, including 223 women (228 babies) with gestational PAM and 467 women (478 babies) with postpartum PAM. The incidence of in situ PAM increased 8.7% (95% CI: 4.0-13.5) per year between 2002 and 2013. The incidence of localized primary invasive PAM did not increase between 1994 and 2013. No significant maternal or neonatal morbidities were identified. Sixteen deaths were observed in women diagnosed with localized primary invasive PAM. The mortality rate for women with gestational PAM did not differ significantly from women with postpartum PAM (2.4/1000 person-years vs. 1.6/1000 person-years, p value = 0.394). CONCLUSIONS: Diagnosis of early PAM in pregnancy or postpartum is not associated with significant adverse outcomes for women or their babies. Early diagnosis remains important to ensure appropriate treatment and positive outcomes.
引用
- Fotheringham P, Safi N, Martin LK, et al. In situ and localized primary invasive pregnancy-associated melanoma: Maternal and perinatal outcomes. J Eur Acad Dermatol Venereol. 2025. PMID: 40823991. doi:10.1111/jdv.20894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。